Previous 10 | Next 10 |
2024-03-14 10:42:03 ET More on Madrigal Pharma Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potentia...
2024-03-13 13:29:04 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...
2024-03-13 08:00:58 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) shares rose in early trading on Wednesday after the company reported positive results from a mid-stage trial of its investigational drug to treat a type of fatty liver disease.... Read the full article on S...
2024-03-09 05:52:00 ET Eli Lilly has been on a roll. The big drugmaker won U.S. regulatory approval for weight loss drug Zepbound in November 2023. Over the last 12 months, Lilly's share price has skyrocketed more than 140%. Lilly has also claimed the mantle of the biggest healthcare co...
2024-03-08 15:00:00 ET More on the markets S&P 500: Time To Hedge, Here's How How The S&P 500 Could Actually Be Closer To 4,200 Than 5,000 SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat ETFs...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
2024-03-06 14:32:51 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...
2024-03-05 10:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting February 2024 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling...
2024-03-05 08:37:00 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...
MAA submission is supported by positive results from MAESTRO-NASH, the only Phase 3 trial in NASH to achieve fibrosis reduction and NASH resolution primary endpoints Resmetirom new drug application is currently under review with the FDA with a PDUFA date of March 14, 2024 CONSHO...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...